.png){kind=icon}
返回期刊详情
Cancer
IF5.1
论文数21163
被引数62240
期刊论文 21163
发表时间
.png){kind=icon}
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemiaI期剂量递增和扩展试验：双特异性CD47抑制剂和CD40激动剂Fc融合蛋白SL-172154（SIRPα-Fc-CD40L）在具有高风险骨髓增生异常综合征或急性髓系白血病患者中的应用.png)
Cancer.png)
OAAI
.png)
分享.png)
收藏
CancerIF5.1
OAAI分享收藏Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late-stage incidence end points and post-trial ongoing evaluation—The Peachtree Consensus美国癌症协会关于多癌种早期检测试验的设计、实施、分析和报告（以晚期发病终点和试验后持续评估为对象）的建议——桃树共识CancerOAAI分享收藏
CancerIF5.1
OAAI分享收藏